Marker Therapeutics, Inc. (MRKR) › Net IncomeMarker Therapeutics, Inc. (MRKR) — Net IncomeAnnual figures by fiscal year, from SEC filings.2000: -$935.3K2001: -$672.0K2002: -$2.28M2003: -$5.78M2004: -$2.68M2005: -$985.6K2006: -$1.30M2007: -$3.89M2008: -$2.20M2009: -$17.35M2010: -$3.53M2011: -$2.03M2013: -$5.53M2014: -$30.88M2015: -$34.07M2016: -$2.46M2017: -$10.98M2018: -$147.96M2019: -$21.43M2020: -$28.71M2021: -$41.88M2022: -$29.93M2023: -$8.24M2024: -$10.73M2025: -$12.16M-$12.16M2000Net Income (USD)2025Fiscal YearNet IncomeChange YoY2025-$12.16M-13.3%2024-$10.73M-30.3%2023-$8.24M+72.5%2022-$29.93M+28.5%2021-$41.88M-45.9%2020-$28.71M-34.0%2019-$21.43M+85.5%2018-$147.96M-1247.3%2017-$10.98M-347.3%2016-$2.46M+92.8%2015-$34.07M-10.3%2014-$30.88M-458.2%2013-$5.53M—2011-$2.03M+42.6%2010-$3.53M+79.6%2009-$17.35M-690.0%2008-$2.20M+43.6%2007-$3.89M-198.3%2006-$1.30M-32.3%2005-$985.6K+63.3%2004-$2.68M+53.6%2003-$5.78M-152.9%2002-$2.28M-240.0%2001-$672.0K+28.2%2000-$935.3K—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share